9/14/2010

Incyte said the FDA has agreed on a design for the late-stage trial of INCB18424, the company's experimental treatment for polycythemia vera. The blood disorder is characterized by the overproduction of red blood cells in the bone marrow. The study aims to have 300 participants.

Related Summaries